Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype

References

• Dillman R O, Davis R B, Green M R, Weiss R B, Gottlieb A J, Caplan S, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 1991; 78: 2520–2526
   PubMed Web of Science ®Google Scholar
• Bishop J F. The treatment of adult acute myeloid leukemia. Semin Oncol 1997; 22: 57–69
   Google Scholar
• Slovak M L, Kopecky K J, Cassileth P A, Harring D H, Theil K S, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075–4083
   PubMed Web of Science ®Google Scholar
• Wheatley K, Burnett A K, Goldstone A H, Gray R G, Hann I M, Harrison C J, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukemia derived from the MRC AML 10 trial. Br J Hematol 1999; 107: 69–79
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison C J, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood 2001; 98: 1312–1320
   PubMed Web of Science ®Google Scholar
• Buchner T, Hiddermann W, Wormann B, Loffler H, Grassmann W, Haferlach T, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with Daunorubicin and 6-Thiogunine: a randomized trial by the German AML Cooperative Group. Blood 1999; 93: 4116–4124
   PubMed Web of Science ®Google Scholar
• Schlenk R F, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia 2003; 17: 1521–1528
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Talpaz M, Santini V, Murgo A, Cheson B, O'Brien S M. Homoharringtonine: history, current research, and future directions. Cancer 2001; 92: 1591–1605
   PubMed Web of Science ®Google Scholar
• Ni D, Ho D H, Vijjeswarapu M, Felix E, Rhea P R, Newman R A. Metabolism of homoharringtonine, a cytotoxic component of the evergreen plant Cephalotaxus harringtonia. J Exp Ther Oncol 2003; 3: 47–52
   PubMedGoogle Scholar
• Lou Y, Jin J, Xu W, Yingjun L, Jie J, Weilai X, Xiangming T. Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP). Am J Hematol 2004; 76: 199–204
   PubMed Web of Science ®Google Scholar
• Bian S, Wang Z, Hao Y, Yan W, Yang T, Qian L, et al. Combination chemotherapy for acute nonlymphoblastic leukemia in adult: a comparison of HAT and D(A)AT protocols. Chin J Hematol 1988; 9: 449–452
   Google Scholar
• Bian S, Hao Y, Wang Z, Yan W, Yang T, Qian L, et al. Results of 91 acute nonlymphoblastic leukemia patients treated with intensive chemotherapy. Chin J Int Med 1990; 29: 22–25
   PubMedGoogle Scholar
• Bian S, Hao Y, Wang Z, Qian L, Yang T, Xue Y, et al. Study on chemotherapy of adult acute nonlymphoblastic leukemia: a comparison of short and long term effectiveness between HA and DA(T) regimens. Chin J Hematol 1993; 14: 59–62
   Google Scholar
• Xue Y, Bian S, Meng Q, Mi Y, Yang D, Zhang Y, et al. HAD combination chemotherapy for adult acute nonlymphoblastic leukemia. Chin J Hematol 1995; 16: 59–61
   Google Scholar
• Xue Y, Bian S, Zhao Y, Mi Y, Meng Q, Wang M, et al. Comparison of 4 groups triple-drug combination chemotherapy for adult acute nonlymphoblastic leukemia. Chin J Hematol 2002; 23: 33–34
   Google Scholar
• Slovak M L, Kopecky K J, Cassileth P A, Harrington D H, Theil K S, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075–4083
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322–2333
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison C J, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312–1320
   PubMed Web of Science ®Google Scholar
• Byrd J C, Mrozek K, Dodge R K, Carall A J, Edwards C G, Arthur D C, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–4336
   PubMed Web of Science ®Google Scholar
• Liu S, Mi Y, Liu X, Xue Y, Wang M, Bian S, et al. Analysis of prognostic factors in Ph-positive adult acute lymphoblastic leukemia. Chin J Hematol 2004; 25: 417–420
   Google Scholar
• Mitelman F. ISCN. An International System for Human Cytogenetics Nomenclature. Karger, BaselSwitzerland 1995
   Google Scholar
• Berman E, Helle G R, Santorsa J, McKenzie S, Gee T, Kempin S, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666–1674
   PubMed Web of Science ®Google Scholar
• Volger W R, Velez-Garcia E, Weiner R S, Flaum M A, Bartolucci A A, Omura G A, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 1992; 10: 1103–1111
   PubMed Web of Science ®Google Scholar
• Schlenk R F, Benner A, Hartmann F, de Valle F, Weber C, Pralle H, et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia 2003; 17: 1521–1528
   PubMed Web of Science ®Google Scholar
• Mrozek K, Heerema N A, Bloomfield C D. Cytogenetics in acute leukemia. Blood Rev 2004; 18: 115–136
   PubMed Web of Science ®Google Scholar
• Byrd J C, Dodge R K, Carroll A, Baer M R, Edwards C, Stamberg J, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999; 17: 3767–3775
   PubMed Web of Science ®Google Scholar
• Mrozek K, Heinonen K, Lawrence D, Carroll A J, Kodaru P R, Rao K W, et al. Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocation involving band 11q23: a Cancer and Leukemia Group B study. Blood 1997; 90: 4532–4538
   PubMed Web of Science ®Google Scholar
• Farag S S, Archer K J, Mrozek K, Vardiman J W, Carroll A J, Pettenati M J, et al. Isolated trisomy of chromosomes 8, 11, 13, and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Int J Oncol 2002; 21: 1041–1051
   PubMed Web of Science ®Google Scholar
• Mi Y, Bian S, Xue Y, Wang J, Meng Q, Zhao Y, et al. Preliminary study on postremission therapy courses in acute myeloid leukemia. Chin J Hematol 2001; 22: 520–523
   Google Scholar